Xenon Pharmaceuticals XENE
$37.04 −$0.52 (-1.38%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $37.04 0.00%
Open$37.22
Prev close$37.56
Day range$36.81 – $37.97
Volume1.09M
Market cap$3.64B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$120.07M-24.6% YoY
Net profit-$110.44M-21.5% YoY
Diluted EPS-$1.11+3.5% YoY
Free cash flow-$90.61M-25.8% YoY
Operating cash flow-$90.33M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-50.3%
Return on assets-47.4%
Return on invested capital-54.0%
Current ratio21.19
Liabilities / assets4.5%
Cash & investments$950.80M
Total debt$4.86M
Net cash (debt)$945.94M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $0.00 | $0.00 | $0.00 | $7.50M | $0.00 |
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $7.50M | $0.00 |
| Operating Expense | $120.07M | $123.16M | $112.33M | $380.57M | $109.77M |
| Selling and Admin Expenses | $24.42M | $23.93M | $23.82M | $79.63M | $22.07M |
| -General & Admin Expense | $24.42M | $23.93M | $23.82M | $79.63M | $22.07M |
| Research & Development | $95.65M | $99.22M | $88.51M | $300.94M | $87.70M |
| Operating Profit | -$120.07M | -$123.16M | -$112.33M | -$373.07M | -$109.77M |
| Net Non-Operating Interest Income (Expense) | $11.62M | $12.15M | $6.91M | $26.83M | $5.34M |
| Non-Operating Interest Income | $11.62M | $12.15M | $6.91M | $26.83M | $5.34M |
| Other Income (Expense) | -$142,000.00 | -$311,000.00 | $548,000.00 | $1.35M | -$296,000.00 |
| Gain on Sale of Security | -$142,000.00 | -$311,000.00 | $548,000.00 | $1.35M | -$296,000.00 |
| Pretax Profit | -$108.59M | -$111.32M | -$104.87M | -$344.89M | -$104.72M |
| Tax | $1.84M | -$585,000.00 | -$2.57M | $1.02M | $538,000.00 |
| Net Profit | -$110.44M | -$110.74M | -$102.30M | -$345.91M | -$105.26M |
| Profit from Continuing Operations | -$110.44M | -$110.74M | -$102.30M | -$345.91M | -$105.26M |
| Net Income to Parent Company | -$110.44M | -$110.74M | -$102.30M | -$345.91M | -$105.26M |
| Net Income to Common Stockholders | -$110.44M | -$110.74M | -$102.30M | -$345.91M | -$105.26M |
| Basic EPS | -$1.11 | -$1.11 | -$1.17 | -$4.36 | -$1.31 |
| Diluted EPS | -$1.11 | -$1.11 | -$1.17 | -$4.36 | -$1.31 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $1.20B | $1.30B | $1.39B | $633.16M | $633.16M |
| Total Current Assets | $960.07M | $945.87M | $1.11B | $560.65M | $560.65M |
| Cash and Cash Equivalents & Short-Term Investments | $950.80M | $930.69M | $1.09B | $548.89M | $548.89M |
| -Cash and Cash Equivalents | $82.56M | $119.53M | $545.87M | $199.16M | $199.16M |
| -Short Term Investments | $868.24M | $811.16M | $548.88M | $349.72M | $349.72M |
| Receivables | $1.17M | $1.63M | $1.17M | $1.37M | $1.37M |
| -Accounts Receivable | $1.17M | $1.63M | $1.17M | $1.37M | $1.37M |
| Other Current Assets | $8.10M | $13.55M | $10.72M | $10.39M | $10.39M |
| Total Non-Current Assets | $239.81M | $349.90M | $280.18M | $72.51M | $72.51M |
| Net PPE | $12.52M | $13.16M | $14.58M | $15.35M | $15.35M |
| -Gross PPE | $12.52M | $13.16M | $14.58M | $30.80M | $30.80M |
| Investments and Advances | $202.68M | $314.41M | $244.87M | $37.15M | $37.15M |
| -Available for Sale Securities | $202.68M | $314.41M | $244.87M | $37.15M | $37.15M |
| Non-Current Prepaid Assets | $9.16M | $7.97M | $8.31M | $7.15M | $7.15M |
| Non-Current Deferred Assets | $15.46M | $14.36M | $12.42M | $12.86M | $12.86M |
| Total Liabilities | $53.49M | $53.38M | $48.99M | $51.40M | $51.40M |
| Total Current Liabilities | $45.30M | $45.01M | $39.82M | $41.79M | $41.79M |
| Payables | $2.03M | $3.42M | $6.02M | $4.20M | $4.20M |
| -Accounts Payable | $1.93M | $2.48M | $5.75M | $3.89M | $3.89M |
| -Total Tax Payable | $106,000.00 | $935,000.00 | $269,000.00 | $313,000.00 | $313,000.00 |
| Current Accrued Expenses | $27.52M | $29.23M | $24.61M | $21.60M | $21.60M |
| Short-Term Debt and Capital Lease Obligation | $1.15M | $1.34M | $1.56M | $1.53M | $1.53M |
| -Current Capital Lease Obligation | $1.15M | $1.34M | $1.56M | $1.53M | $1.53M |
| Total Non-Current Liabilities | $8.19M | $8.37M | $9.18M | $9.61M | $9.61M |
| Long Term Debt and Capital Lease Obligation | $4.86M | $5.08M | $5.93M | $6.41M | $6.41M |
| -Long Term Capital Lease Obligation | $4.86M | $5.08M | $5.93M | $6.41M | $6.41M |
| Other Non-Current Liabilities | $3.33M | $3.29M | $3.25M | $3.20M | $3.20M |
| Total Equity | $1.15B | $1.24B | $1.34B | $581.76M | $581.76M |
| Stockholders' Equity | $1.15B | $1.24B | $1.34B | $581.76M | $581.76M |
| Capital Stock | $2.49B | $2.43B | $2.42B | $1.60B | $1.60B |
| -Common Stock | $2.49B | $2.43B | $2.42B | $1.60B | $1.60B |
| Additional Paid-In Capital | $227.29M | $276.85M | $264.88M | $228.23M | $228.23M |
| Retained Earnings | -$1.57B | -$1.46B | -$1.35B | -$1.25B | -$1.25B |
| Gains/Losses Not Affecting Retained Earnings | -$5.05M | -$2.66M | -$1.21M | $335,000.00 | $335,000.00 |
| -Accumulated Depreciation | – | – | – | -$15.45M | -$15.45M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$90.33M | -$95.39M | -$88.90M | -$279.12M | -$81.48M |
| Net cash flow from continuing operations | -$90.33M | -$95.39M | -$88.90M | -$279.12M | -$81.48M |
| Net Income from Continuing Operations | -$110.44M | -$110.74M | -$102.30M | -$345.91M | -$105.26M |
| Gain/Loss from Continuing Operations | $36,000.00 | -$725,000.00 | -$604,000.00 | $698,000.00 | $179,000.00 |
| Depreciation & Depletion & Amortization | $562,000.00 | $558,000.00 | $587,000.00 | $2.54M | $611,000.00 |
| Deferred Tax | -$1.10M | -$1.94M | $447,000.00 | -$3.20M | -$1.11M |
| Other Non-Cash Items | $330,000.00 | $1.20M | -$539,000.00 | $1.31M | $334,000.00 |
| Change in Working Capital | $4.95M | $2.43M | -$3.38M | $4.36M | $8.97M |
| -Change in Receivables | $462,000.00 | -$467,000.00 | $205,000.00 | $104,000.00 | -$559,000.00 |
| -Change in Prepaid Assets | $4.31M | -$2.50M | -$1.48M | -$3.16M | $6.63M |
| -Change in Payables and Accrued Expense | $499,000.00 | $5.72M | -$1.80M | $5.51M | $3.19M |
| -Change in Other Current Liabilities | -$459,000.00 | -$317,000.00 | -$302,000.00 | $1.90M | $2.86M |
| Net cash flow from investing | $53.19M | -$331.24M | -$407.28M | $218.00M | $62.70M |
| Net Cash Flow from Continuing Investing Activities | $53.19M | -$331.24M | -$407.28M | $218.00M | $62.70M |
| Net PPE Purchase and Sale | -$284,000.00 | -$275,000.00 | -$133,000.00 | -$799,000.00 | -$318,000.00 |
| Net Investment Purchase and Sale | $53.48M | -$330.96M | -$407.15M | $218.80M | $63.02M |
| Financing Cash Flow | $228,000.00 | $26,000.00 | $843.01M | $117.11M | $113.54M |
| Net Cash Flow from Continuing Financing Activities | $228,000.00 | $26,000.00 | $843.01M | $117.11M | $113.54M |
| Net Common Stock Issuance | $0.00 | $0.00 | $837.53M | $112.15M | $112.15M |
| Proceeds from Stock Option Exercised | $228,000.00 | $26,000.00 | $5.49M | $4.96M | $1.39M |
| Ending Cash Balance | $82.56M | $119.53M | $545.87M | $199.16M | $199.16M |
| Net Change in Cash | -$36.91M | -$426.60M | $346.83M | $55.99M | $94.75M |
| Beginning Cash Balance | $119.53M | $545.87M | $199.16M | $142.71M | $104.51M |
| Effect of Exchange Rate Changes | -$57,000.00 | $262,000.00 | -$130,000.00 | $458,000.00 | -$104,000.00 |
| Free Cash Flow | -$90.61M | -$95.67M | -$89.03M | -$279.92M | -$81.80M |
No comments yet — be the first to weigh in on XENE.
Sign in to join the discussion.